HARMONY BIOSCIENCES HLDG INC (HRMY)
Health Care · Biotechnology · NASDAQ
Harmony Biosciences is a pharmaceutical company focused on delivering innovative therapies for rare neurological disorders, anchored by its commercial success in narcolepsy treatment.
What HARMONY BIOSCIENCES HLDG INC does
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare and other neurological diseases. The company markets WAKIX (pitolisant), a first-in-class medicine for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Themes: rare diseases, neurology, narcolepsy treatments, sleep medicine
Fundamentals
- Price$38.15 as of 2026-08-21 close
- Market cap$2.2B as of 2026-08-21
- 1-year return+2.3% 2025-08-21 close $37.29 → 2026-08-21 close $38.15
- P/E12.45 as of 2026-08-24
- Net margin+18.9% as of 2026-08-24
- Gross margin+75.4% as of 2026-08-24
- ROE+20.1% as of 2026-08-24
- Debt / equity0.15 as of 2026-08-24
- Revenue growth (YoY)+24.3% as of 2026-08-24
- Revenue CAGR (3y)+25.6% SEC XBRL
- Beta1.01 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How HRMY compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
HRMY is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
54.8 #497 of 1,704 scored · #96 of 240 in Health Care
Trend 67th: a strong uptrend, with buyers in control; momentum 65th: over the past 3 months this stock beat the market by 22.0 percentage points; weakest is volume and participation 41st: trading volume is unusually light — only about 45% of its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How HARMONY BIOSCIENCES HLDG INC looks technically
HARMONY BIOSCIENCES HLDG INC (HRMY) is trading 13.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 35 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago. Trading volume is unusually light — only about 45% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 13.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +13.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $36.30 | $36.30 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $33.77 | $33.77 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 35 trading days ago — a "golden cross", a bullish long-term signal | 35 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control | 30.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($36.80 to $40.15) — its "stochastic" reading is 40 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 40.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $40.87 | $40.87 |
|---|---|---|
| From the 52-week high | it is 6.7% below its 52-week high (its highest price of the past year) | -6.7% |
| Above the 52-week low | it is 49.5% above its 52-week low (its lowest price of the past year) | +49.5% |
| Below the 52-week high | it is 6.7% below its highest point of the past year | 6.7% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $62.09 (set on 2022-12-05) | $62.09 |
| Given back of the 52-week move | over the past year its closes ranged ($25.90 to $40.51), and it has given back roughly a quarter of its rise from last year’s low — 16% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.01 to $31.48. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 16.1% |
| From the all-time high | it is 38.6% below its all-time high | -38.5% |
| Nearest price level | it is trading 0.9% below a resistance level at $38.51 — a price it turned at three times since 2025-08-27, most recently on 2026-07-07. Since 2024-08-21 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.9% |
| All-time low | its lowest closing price on record is $18.61 (set on 2023-10-13) | $18.61 |
| Above the all-time low | it is 105.0% above its all-time low | +105.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.35 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.35 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $34.88 and $40.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $34.88 – $37.83 – $40.78 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 3.3 daily ranges above its 200-day average price (13.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 45% of its 30-day average | 0.45× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 4.2% above the previous close 13 sessions ago and has not traded back through the level it left behind at 35.6 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.2% |
| Gap filled | a 5.6% gap down opened on 2026-07-16 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 23 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.2 percentage points (the stock gained 3.6% while the market gained 2.3%) | +1.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 22.0 percentage points (the stock gained 25.1% while the market gained 3.1%) | +22.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 19.8 percentage points (the stock gained 30.8% while the market gained 11.1%) | +19.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 18.2 percentage points (the stock gained 2.3% while the market gained 20.5%) | -18.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.3% of the share price. | +7.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $32.88 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +16.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-07-16 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $36.91 — a volume-weighted average of daily closes over 27 sessions, not a true tick-by-tick VWAP. | +3.4% |
Price levels it has turned at before
HRMY last closed at $38.15 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $38.51 | Resistance | 0.9% above the last close | turned there three times · 2025-08-27 to 2026-07-07 |
| $36.90 | Support | 3.3% below the last close | turned there twice · 2024-11-11 to 2025-12-18 |
| $39.82 | Resistance | 4.4% above the last close | turned there 7 times · 2024-09-16 to 2026-08-13 |
| $36.04 | Support | 5.5% below the last close | turned there 7 times · 2024-10-14 to 2026-06-11 |
| $40.80 | Resistance | 7.0% above the last close | turned there three times · 2024-10-01 to 2025-12-15 |
| $35.00 | Support | 8.3% below the last close | turned there 7 times · 2024-08-28 to 2026-08-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · beating the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.10 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$46.10 range $30.00 – $70.00; median $47.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HRMY
- Consensus EPS estimate$1.47 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant dependence on the continued success and market acceptance of WAKIX.","Potential for intense competition from existing therapies and new market entrants.","Risks associated with regulatory approvals, clinical trial outcomes, and intellectual property protection."]
What changed in the latest 10-Q
AI-assisted comparison of HRMY's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing: Added language 'In some cases, you can identify forward-looking statements by terms such as...' moved to earlier position in the cautionary note (filed 2026-05-07)
- In newer filing: Added bullet point 'other risks and uncertainties identified under the "Risk Factors" section or other portions of this report or other of our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025' (filed 2026-05-07)
- Removed:
- In older filing: Removed reference to 'ZYN002' from the R&D plans bullet point (filed 2025-11-04)
- In older filing: Removed reference to 'BP1-15205' from the R&D plans bullet point (filed 2025-11-04)
- In older filing: Final bullet point 'and' connector removed - older version ended with 'the impact of government laws and regulations.' without additional risk factors bullet (filed 2025-11-04)
- Reworded:
- Preamble change: Older text states 'These statements involve known and unknown risks...' while newer states 'All of our forward-looking statements are qualified in their entirety by reference to known and unknown risks...' (filed 2026-05-07 vs 2025-11-04)
- Risk intro change: Older text says 'Important factors that could cause such differences include, but are not limited to, statements about:' while newer says 'These factors include, but are not limited to, risks and uncertainties relating to:' (filed 2026-05-07 vs 2025-11-04)
- Intellectual property: Older text says 'our intellectual property position' while newer says 'our intellectual property positions' (plural) (filed 2026-05-07 vs 2025-11-04)
- Identifier terms: Older text includes 'potential' with comma before 'or' while newer uses different punctuation placement in the list of forward-looking statement identifiers (filed 2026-05-07 vs 2025-11-04)
- Notes:
- The newer filing text appears truncated at the end; full comparison of closing language could not be completed
- Both versions end mid-sentence at the Form 10-K reference, so complete document structure cannot be verified
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for HRMY — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding HRMY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 14,018,536
- Reported value $392,659,188
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
HRMY had 4,496,943 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
HRMY had 7.72% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.05 days to cover at the same settlement.
- Reported short interest (shares) 4,496,943
- Short interest (% of shares outstanding) 7.72%
- Prior settlement (shares) 5,114,969
- Reported change -12.08%
- Days to cover (reported) 5.05
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Jazz Pharmaceuticals (JAZZ)
- Avadel Pharmaceuticals (AVDL)
- Axsome Therapeutics (AXSM)
- Biogen (BIIB)
- Takeda Pharmaceutical (TAK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HRMY vs…
HARMONY BIOSCIENCES HLDG INC is found in…
Frequently asked questions
What does HARMONY BIOSCIENCES HLDG INC (HRMY) do?
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare and other neurological diseases. The company markets WAKIX (pitolisant), a first-in-class medicine for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
What sector is HARMONY BIOSCIENCES HLDG INC (HRMY) in?
HARMONY BIOSCIENCES HLDG INC (HRMY) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are HARMONY BIOSCIENCES HLDG INC's (HRMY) competitors?
Notable peers of HARMONY BIOSCIENCES HLDG INC (HRMY) include Jazz Pharmaceuticals, Avadel Pharmaceuticals, Axsome Therapeutics, Biogen and Takeda Pharmaceutical. This peer set is informational only — not financial advice.
Is HARMONY BIOSCIENCES HLDG INC (HRMY) overbought or oversold right now?
HARMONY BIOSCIENCES HLDG INC (HRMY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HRMY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.